Clinical recommendations for the prostate-specific antigen in the spanish autonomous communities and cities

Section: Originals

How to quote

Cañabate Blanco M, Álvarez Dardet C, Marcos Marcos J. Recomendaciones clínicas del antígeno prostático específico en las CC.AA. y ciudades autónomas españolas. RIdEC 2022; 15(1):45-53.

Authors

Marina Cañabate Blanco, Carlos Álvarez Dardet, Jorge Marcos Marcos

Position

1 Enfermera.2 Grupo de investigación en Salud Pública. Universidad de Alicante. España.3 Dr. Departamento de Psicología de la Salud. Universidad de Alicante. España.

Contact email: marinaalamoblanco@gmail.com

Abstract

Objective: to review the clinical practice recommendations available in Spain regarding prostate cancer screening, assessing their suitability according to the indications by the U.S Preventive Services Task Force.

Methods: a review of the clinical practice recommendations for prostate cancer screening by the main scientific societies and the health authorities of the autonomous communities. A subsequent comparison with the U.S Preventive Services Task Force.

Results: both the Regional Ministries of Health of the autonomous communities and the scientific societies, except for two who showed ambiguity, have ruled out its routine use and implementation as a program for early detection.

Conclusion: there are still recommendations for PSA testing in asymptomatic men.

Keywords:

Public Health; screening; prostate neoplasiaclinical practice guidelines as subject matter

Versión en Español

Título:

Recomendaciones clínicas del antígeno prostático específico en las CC.AA. y ciudades autónomas españolas